A UNIVERSITY of Glasgow spin-out behind pioneering technology to evaluate drug toxicity and improve patient safety has been boosted by a £2 million investment.
The funding for Clyde Biosciences is led by Epidarex Capital, a venture capital fund focused on early-stage life sciences firms, with backing also coming from the Scottish Investment Bank and Glasgow University Holdings.